National Institutes of Health/National Human Genome Research Institute (NIH/NHGRI)
R21HL126053, R01HL138126, and R01CA207497
米国
引用
ジャーナル: Mol Ther / 年: 2019 タイトル: Protease-Activatable Adeno-Associated Virus Vector for Gene Delivery to Damaged Heart Tissue. 著者: Caitlin M Guenther / Mitchell J Brun / Antonette D Bennett / Michelle L Ho / Weitong Chen / Banghe Zhu / Michael Lam / Momona Yamagami / Sunkuk Kwon / Nilakshee Bhattacharya / Duncan Sousa / ...著者: Caitlin M Guenther / Mitchell J Brun / Antonette D Bennett / Michelle L Ho / Weitong Chen / Banghe Zhu / Michael Lam / Momona Yamagami / Sunkuk Kwon / Nilakshee Bhattacharya / Duncan Sousa / Annicka C Evans / Julie Voss / Eva M Sevick-Muraca / Mavis Agbandje-McKenna / Junghae Suh / 要旨: Adeno-associated virus (AAV) has emerged as a promising gene delivery vector because of its non-pathogenicity, simple structure and genome, and low immunogenicity compared to other viruses. However, ...Adeno-associated virus (AAV) has emerged as a promising gene delivery vector because of its non-pathogenicity, simple structure and genome, and low immunogenicity compared to other viruses. However, its adoption as a safe and effective delivery vector for certain diseases relies on altering its tropism to deliver transgenes to desired cell populations. To this end, we have developed a protease-activatable AAV vector, named provector, that responds to elevated extracellular protease activity commonly found in diseased tissue microenvironments. The AAV9-based provector is initially inactive, but then it can be switched on by matrix metalloproteinases (MMP)-2 and -9. Cryo-electron microscopy and image reconstruction reveal that the provector capsid is structurally similar to that of AAV9, with a flexible peptide insertion at the top of the 3-fold protrusions. In an in vivo model of myocardial infarction (MI), the provector is able to deliver transgenes site specifically to high-MMP-activity regions of the damaged heart, with concomitant decreased delivery to many off-target organs, including the liver. The AAV provector may be useful in the future for enhanced delivery of transgenes to sites of cardiac damage.
#200 - 2016年8月 正二十面体型ウイルスの準対称性 (Quasisymmetry in Icosahedral Viruses) 類似性 (1)
-
集合体
登録構造単位
A: Capsid protein VP1 B: Capsid protein VP1 C: Capsid protein VP1 D: Capsid protein VP1 E: Capsid protein VP1 F: Capsid protein VP1 G: Capsid protein VP1 H: Capsid protein VP1 I: Capsid protein VP1 J: Capsid protein VP1 K: Capsid protein VP1 L: Capsid protein VP1 M: Capsid protein VP1 N: Capsid protein VP1 O: Capsid protein VP1 P: Capsid protein VP1 Q: Capsid protein VP1 R: Capsid protein VP1 S: Capsid protein VP1 T: Capsid protein VP1 U: Capsid protein VP1 V: Capsid protein VP1 W: Capsid protein VP1 X: Capsid protein VP1 Y: Capsid protein VP1 Z: Capsid protein VP1 a: Capsid protein VP1 b: Capsid protein VP1 c: Capsid protein VP1 d: Capsid protein VP1 e: Capsid protein VP1 f: Capsid protein VP1 g: Capsid protein VP1 h: Capsid protein VP1 i: Capsid protein VP1 j: Capsid protein VP1 k: Capsid protein VP1 l: Capsid protein VP1 m: Capsid protein VP1 n: Capsid protein VP1 o: Capsid protein VP1 p: Capsid protein VP1 q: Capsid protein VP1 r: Capsid protein VP1 s: Capsid protein VP1 t: Capsid protein VP1 u: Capsid protein VP1 v: Capsid protein VP1 w: Capsid protein VP1 x: Capsid protein VP1 y: Capsid protein VP1 z: Capsid protein VP1 1: Capsid protein VP1 2: Capsid protein VP1 3: Capsid protein VP1 4: Capsid protein VP1 5: Capsid protein VP1 6: Capsid protein VP1 7: Capsid protein VP1 8: Capsid protein VP1